We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Visage Imaging Debuts AI Offerings at Chicago Show

By HospiMedica International staff writers
Posted on 27 Nov 2017
Visage Imaging, Inc. More...
(Richmond, VIC, Australia) debuted its artificial intelligence (AI) offerings at the Radiological Society of North America (RSNA) 2017 annual meeting as part of the inaugural RSNA Machine Learning Showcase (November 26-30, Chicago, Illinois).

Visage aims to utilize its R&D capability and market leading technology to deliver cutting-edge AI offerings to optimize Enterprise Imaging worldwide. At RSNA 2017, the company showcased Visage 7 and the technology, which makes it the first and only system to combine both AI research and AI-assisted diagnostic interpretation in the same Enterprise Imaging platform.

“Historically, imaging platforms for research and diagnostic purposes have been totally separate. Visage’s GPU-based architecture is ideal for AI and, combined with our open APIs, will enable us to unify research and diagnostic imaging in ways not available before,” said Malte Westerhoff, PhD, co-founder and global CTO of Visage Imaging. “This will enable AI breakthroughs to advance patient care by giving radiologists faster access to new tools that help increase productivity and improve clinical accuracy.”

The company will also show algorithms working on the ultrafast and highly scalable Visage 7 Enterprise Imaging Platform. Both internally developed algorithms as well as third party algorithms from academic institutions and other companies will be demonstrated.

“AI is evolving rapidly and has the potential to transform Enterprise Imaging in ways previously not imagined,” said Dr. Sam Hupert, CEO of Visage Imaging. “We are well placed to capitalize on this transformation as we look to leverage our three key assets, namely our R&D capability, our technology platform and our growing base of blue chip clients.”

The company’s first AI innovations for Visage 7 are works-in-progress and are scheduled to be released in the first half of 2018.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.